Salerno Pharms

Salerno Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative therapies for metabolic and liver diseases. The company's lead candidate, SAL-001, is an oral small molecule currently in Phase 2 development for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). Salerno Pharms also maintains a pipeline targeting other high-impact conditions, including cholestatic liver diseases and obesity. By optimizing known therapeutic pathways, the company aims to provide effective treatments for patients with significant unmet medical needs in the hepatology space. Headquartered in Brooksville, Florida, Salerno Pharmaceuticals is led by a team with extensive experience in metabolic medicine and drug development.